23.81
+0.37(+1.58%)
Currency In USD
| Previous Close | 23.44 |
| Open | 23.48 |
| Day High | 23.83 |
| Day Low | 23.26 |
| 52-Week High | 23.83 |
| 52-Week Low | 8.73 |
| Volume | 5.65M |
| Average Volume | 8.06M |
| Market Cap | 16.56B |
| PE | -24.05 |
| EPS | -0.99 |
| Moving Average 50 Days | 21.22 |
| Moving Average 200 Days | 14.62 |
| Change | 0.37 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $2,289.42 as of January 15, 2026 at a share price of $23.81. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 5 years ago, it would be worth $2,324.06 as of January 15, 2026 at a share price of $23.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roivant announces positive updates to timing guid
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
GlobeNewswire Inc.
Oct 27, 2025 8:10 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease,